Objective To explore the effect of berberine hydrochloride on serum HIF-1α,Caspase -3 levels in patients with acute cerebral infarction with a multicenter study.Methods 126 patients with acute cerebral infarction from January 2012 to January 2014 were selected in the Affiliated Hospital of Hebei Engineering University,the First Hospital of Handan City,Handan Central Hospital were divided into experimental groups and control group using random number table.Control group had 63 cases,were given 80 mg ozagrel sodium injection intravenously,twice a day,and 800 mg calf blood protein injection intravenously,once per day on the basis of conventional treatment;at the same time,100 mg of oral aspirin tablets were taken,once per night,7 days for a course of treatment.Experimental group were given berberine hydrochloride on the basis of conventional treatment,0.7 g orally,three times a day,7 days for a course of treatment.After a course of treatment,serum HIF-1α,Caspase-3 levels in patients with acute cerebral infarction were observed before and after treatment.Results Serum HIF-1αlevels in two groups were reduced after treatment,and its level in experimental group[(733.49 ±225.01)ng/mL]was lower than that in control group [(975.32 ±311.35)ng/mL],the difference was statistically significant (P<0.05 ).Serum Caspase-3 levels in two groups after treatment were decreased,and its level in experimental group [(1 1.88 ±2.66 )ng/mL]was lower than the control group [(12.51 ±3.77)ng/mL],the difference was statistically significant (P <0.05).Conclusion Berberine hydrochloride could improve the serum HIF-1α,Caspase-3 levels in patients with acute cerebral infarction,reduce the fatality rate,and could be actively used in the recovery of patients with acute cerebral infarction treatment.

ObjectiveTo explore the rehabilitation outcome of personalized pulmonary rehabilitation therapy in pneumoconiosis patients in the rehabilitation station. Methods A total of 42 pneumoconiosis patients were selected as the study subjects from seven pneumoconiosis rehabilitation stations in Xinjiang Uygur Autonomous Region using the judgment sampling method. Patients were treated with personalized rehabilitation therapy for three months, and the outcome was analyzed. Results The six-minute walking test distance, maximum inspiratory pressure, maximum expiratory pressure, forced vital capacity (FVC), forced expiratory volume in one second (FEV₁), and FEV₁/FVC ratio of the pneumoconiosis patients were higher after rehabilitation therapy than those before therapy (all P<0.05). The score of Chronic Obstructive Pulmonary Disease Assessment Test of patients after therapy was lower than that in pre-treatment (P<0.05). There was no significant difference in respiratory difficulty, Borg scale, balance ability, depression symptoms, anxiety symptoms, nutritional status scores, body mass index, blood oxygen saturation, and heart rate before and after rehabilitation therapy (all P>0.05). Conclusion The individualized pulmonary rehabilitation therapy of pneumoconiosis patients at pneumoconiosis rehabilitation station can improve the respiratory muscle strength and lung function of patients, and improve their quality of life.

Anlotinib has strong antiangiogenic effects and leads to vessel normalization.However,the"window period"characteristic in regulating vessel normalization by anlotinib cannot fully explain the long-term survival benefits achieved through combining it with other drugs.In this study,through RNA sequencing(RNA-seq)and label-free quantitative proteomics analysis,we discovered that anlotinib regulated the expression of components of the extracellular matrix(ECM),leading to a significant reduction in ECM stiffness.Our bioinformatic analysis revealed a potential positive relationship between the ECM pathway and gefitinib resistance,poor treatment outcomes for programmed death 1(PD-1)targeting,and unfavourable prognosis following chemotherapy in lung cancer patients.We administered anlotinib in combination with these antitumour drugs and visualized their distribution using fluorescent labelling in various tumour types.Notably,our results demonstrated that anlotinib prolonged the retention time and distribution of antitumour drugs at the tumour site.Moreover,the combination therapy induced notable loosening of the tumour tissue structure.This reduction was associated with decreased interstitial fluid pressure and tumour solid pressure.Additionally,we observed that anlotinib effectively suppressed the Ras homologue family member A(RhoA)/Rho-associated protein kinase(ROCK)signalling pathway.These findings suggest that,in addition to its antiangiogenic and vessel normalization effects,anlotinib can increase the distribution and retention of antitumour drugs in tumours by modulating ECM expression and physical properties through the RhoA/ROCK signalling pathway.These valuable insights contribute to the development of combination therapies aimed at improving tumour targeting in cancer treatment.